Literature DB >> 33247433

Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.

Justin Spivey1, Rebekah Wrenn1, Beiyu Liu2, Eileen Maziarz3, Bridgette Kram1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Invasive fungal infections often occur in patients with comorbidities that complicate oral administration. Serum concentrations of isavuconazole were characterized after enteral tube administration. CASE DESCRIPTION: Thirteen of 14 isavuconazole concentrations were >1 mg/dl (median 1.6 mg/dl) among those receiving enteral tube administration, which was comparable to intravenous (median 1.9 mg/dl). Higher concentrations were observed during oral administration (median 3 mg/dl). WHAT IS NEW AND
CONCLUSION: Administration of isavuconazole via tube resulted in concentrations comparable to FDA-approved routes of administration. This route may be feasible and appropriate for select patients.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  enteral administration; invasive fungal infection; isavuconazole; therapeutic drug monitoring

Year:  2020        PMID: 33247433      PMCID: PMC7969444          DOI: 10.1111/jcpt.13317

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  13 in total

1.  Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.

Authors:  Erin K McCreary; M Hong Nguyen; Matthew R Davis; Jared Borlagdan; Ryan K Shields; Anthony D Anderson; Ryan M Rivosecchi; Rachel V Marini; Lauren M Sacha; Fernanda P Silveira; David R Andes; Alexander J Lepak
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

2.  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

Authors:  Jodi M Lestner; Steven A Roberts; Caroline B Moore; Susan J Howard; David W Denning; William W Hope
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

3.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Authors:  Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

4.  Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.

Authors:  Meagan L Adamsick; Ramy H Elshaboury; Thais Gift; Michael K Mansour; Camille N Kotton; Ronak G Gandhi
Journal:  Transpl Infect Dis       Date:  2019-01-29       Impact factor: 2.228

5.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

6.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.

Authors:  Wan Beom Park; Nak-Hyun Kim; Kye-Hyung Kim; Seung Hwan Lee; Won-Seok Nam; Seo Hyun Yoon; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam Joong Kim; In-Jin Jang; Myoung-Don Oh; Kyung-Sang Yu
Journal:  Clin Infect Dis       Date:  2012-07-03       Impact factor: 9.079

7.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

Authors:  Benjamin J Park; Peter G Pappas; Kathleen A Wannemuehler; Barbara D Alexander; Elias J Anaissie; David R Andes; John W Baddley; Janice M Brown; Lisa M Brumble; Alison G Freifeld; Susan Hadley; Loreen Herwaldt; James I Ito; Carol A Kauffman; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Genovefa Papanicolaou; Thomas F Patterson; Trish M Perl; Mindy G Schuster; Randall Walker; John R Wingard; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

10.  Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Authors:  Amit V Desai; Laura L Kovanda; William W Hope; David Andes; Johan W Mouton; Donna L Kowalski; Robert W Townsend; Salim Mujais; Peter L Bonate
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.